Free Trial

More results...

Filter by Content types
Filter by Geography

Alerts LATEST ALERTS

  • China - United States Modified trade tariffs temporarily suspended ...
  • New York - United States Sales of vape and pre-roll cannabis products paused for investigation ...
  • South Africa Draft law for cannabis food products to be published ‘soon’ ...
  • Indonesia BNN to launch scientific study on medical cannabis benefits ...
  • Oklahoma - United States Bills modifying medical cannabis laws await governor approval ...
  • Alabama - United States Bill to regulate hemp products passes House and Senate ...
  • Italy Drug use has to affect ability before drivers can be penalised ...
  • Netherlands Minister reports on medical cannabis policy changes ...
  • Australia Medical cannabis cultivators want local production prioritised ...
  • Latvia Progressives to propose legalisation of medical cannabis ...
  • Australia No changes expected following election results ...
  • Oklahoma - United States Governor calls for enforcement against IHDC products ...
News analysis

Italy’s top court rules that oral CBD products are prescription drugs

Written by || 30th April 2025 || News analysis | Cannabis – medical | Cannabis – recreational | CBD | Cosmetics | Food | Health and science | Hemp | Regulation and legislation | GeographiesEurope Italy

Italy’s Regional Administrative Court (TAR) has dismissed an appeal challenging the Ministry of Health’s decree to classify oral CBD products as narcotics.

This decision, taken on 16th April, was based on the precautionary principle, as it took into account the potential for trace amounts of THC in CBD oil, which may pose health risks or cause dependence.

Unlock access

Want the full analysis? Let's talk

We share insights with professionals we’re in contact with. Let us know a bit about your interest.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Want the full analysis? Let's talk

We share insights with professionals we’re in contact with. Let us know a bit about your interest.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.